Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 4,683 Shares

Key Points

• CFO Howard Horn sold 4,683 shares on May 1 at an average price of $24.90, reducing his stake to 110,342 shares (a 4.07% ownership decline) and realizing about $116,607.
• Horn has executed multiple insider sales this quarter — roughly 19,410 shares in total across March–May for about $442,000 — indicating a clear pattern of insider selling.
• Ultragenyx shares trade around $24.81 with a $2.44B market cap; the company posted a revenue beat but an EPS miss, and analysts hold a consensus "Moderate Buy" rating with a $60.76 price target.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CFO Howard Horn sold 4,683 shares of the company's stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $24.90, for a total value of $116,606.70. Following the completion of the transaction, the chief financial officer owned 110,342 shares in the company, valued at $2,747,515.80. This represents a 4.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Howard Horn also recently made the following trade(s):

• On Wednesday, April 1st, Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $20.97, for a total value of $98,202.51.
• On Tuesday, March 3rd, Howard Horn sold 1,635 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $22.40, for a total value of $36,624.00.
• On Monday, March 2nd, Howard Horn sold 8,409 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $22.70, for a total value of $190,884.30.

Ultragenyx Pharmaceutical Price Performance

RARE traded up $0.04 during trading hours on Monday, reaching $24.81. The company's stock had a trading volume of 1,849,141 shares, compared to its average volume of 2,251,130. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $18.29 and a fifty-two week high of $42.37. The stock has a market cap of $2.44 billion, a PE ratio of -4.25 and a beta of 0.39. The business's 50-day moving average is $22.50 and its 200-day moving average is $26.96.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The firm had revenue of $207.28 million for the quarter, compared to analyst estimates of $199.60 million. During the same quarter last year, the company earned ($1.39) earnings per share. The firm's revenue for the quarter was up 25.5% on a year-over-year basis. Analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.49 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on RARE. JPMorgan Chase & Co. decreased their price target on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an "overweight" rating on the stock in a research note on Thursday, March 12th. Morgan Stanley upped their price target on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the stock an "overweight" rating in a research note on Thursday, April 16th. Truist Financial upgraded Ultragenyx Pharmaceutical to a "strong-buy" rating in a research note on Wednesday, March 25th. HC Wainwright decreased their price target on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, February 17th. Finally, Barclays decreased their price target on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $60.76.

Institutional Trading of Ultragenyx Pharmaceutical

Large investors have recently modified their holdings of the stock. Aquatic Capital Management LLC increased its holdings in Ultragenyx Pharmaceutical by 79.1% in the third quarter. Aquatic Capital Management LLC now owns 191,458 shares of the biopharmaceutical company's stock valued at $5,759,000 after buying an additional 84,559 shares during the last quarter. SG Americas Securities LLC purchased a new position in Ultragenyx Pharmaceutical in the third quarter valued at $3,773,000. Aberdeen Group plc increased its holdings in Ultragenyx Pharmaceutical by 94.3% in the third quarter. Aberdeen Group plc now owns 973,656 shares of the biopharmaceutical company's stock valued at $29,288,000 after buying an additional 472,600 shares during the last quarter. Thornburg Investment Management Inc. purchased a new position in Ultragenyx Pharmaceutical in the third quarter valued at $2,083,000. Finally, WCM Investment Management LLC increased its holdings in Ultragenyx Pharmaceutical by 36.9% in the third quarter. WCM Investment Management LLC now owns 288,109 shares of the biopharmaceutical company's stock valued at $8,747,000 after buying an additional 77,640 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.